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ABSTRACT
Large-scale randomized clinical trials are usually used to compare therapeutic effect of a
new treatment to that of a standard treatment. Interim analyses are often performed at
several occasions prior to the definitive analysis so that investigators can stop a trial early
for ethical or economic reasons if the accumulating data shows enough evidence of superior-
ity or futility of the new treatment. It has been recognized that the boundaries for the test
statistics at those interim analyses need to be adjusted so that the overall type I error can
be properly controlled. In contrary to adjustment for multiple testing in general practice,
the theory on adjustment on boundaries for interim analyses have been well developed in
past decades because of their sequential nature. At an interim analysis, one may be inter-
ested in estimating the chance for demonstrating the expected efficacy benefit from the new
treatment at the definitive analysis. Conditional power provides such assessment based on
currently available empirical data. Here we review and compare the operating characteristics
of some fundamental methods and extensions in regulating the spending of exit probabilities
at interim analyses under the null so that the overall type I error is controlled at the desired
nominal level. Then we review the development and calculation of conditional power under
a few typical settings. We have applied a few methods on planning of interim analyses and
the usage of conditional power to two trials from the National Surgical Adjuvant Breast and
iv
Bowel projects. Well-planned and scientifically-sound early termination of clinical trials save 
lives, time and expense in the development of better treatments or regimens. Appropriate use 
of interim analysis design and conditional power, as we promote here, has tremendous public 
health significance in improving the lifespan and life quality of the population.
Keywords: interim monitoring; conditional power; clinical trials.
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1.0 INTRODUCTION TO CLINICAL TRIALS
A new medical therapy may go through several stages of testing on human subjects after
showing promise in animal experiments. Phase I clinical trials mainly concern about human
safety. The aim is to find a suitable dose. Normally, they involve 20 to 80 participants who
may benefit from the treatment under investigation. Once the dose is determined, the next
step is to assess the efficacy of the new treatment. Phase II clinical trials evaluate the bio-
logical effect of the treatment and continue to monitor the safety aspect on a larger scale of
subjects. They usually performed on between 100 and 300 diseased patients. Phase III clin-
ical trials are randomized trials designed to compare the effectiveness of the new treatment
to standard treatment. They usually involve more than 1000 patients and last 3 to 5 years
or longer depending on recruitment rate or follow-up time needed. Therefore, they are very
expensive and time-consuming. It is the Phase III clinical trial draws the most attention of
statistical design and statistical analysis.[Jennison and Turnbull, 1999]
We focus on clinical trials that are aimed to show superiority of a new treatment over a
standard treatment or placebo in the thesis, but there are equivalence studies designed to
show that the efficiency of a treatment is the same as or no worse than the existing treatment
which may be safer, less expensive or easier to use. It should be noted that failure to show
the treatment difference maybe due to small sample size and subsequent low power.
In clinical trials, the endpoint often refers to an outcome variable of interest. It can
belong to various types. A dichotomous outcome of success or failure is common, especially
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in assessment of treatment efficacy. A quantitative outcome is one measured on a contin-
uous scale and is often modeled by a normal distribution after appropriate transformation.
A survival outcome is time of study entry to the first treatment failure or patient death.
Sometimes, we do not observe the event of interest at the time of analysis. In this case, we
say the patient is right censored and record the partial information that the time to event
exceeds the follow-up time.
In any experiment or survey in which data accumulate steadily over a period of time,
it is natural to monitor results as they occur so that actions such as modifications of study
design or early termination can be taken. The many reasons for performing interim analyses
can be categorized into three classes: ethical, administrative and economic. In trials involv-
ing human subjects, there is an ethical need to monitor results to ensure that individuals
are not exposed to an unsafe, inferior or ineffective treatment regimen. Even in negative
trials where there appears to be no difference in the performance of two therapies there is
ethical imperative to terminate a trial as soon as possible so that resources can be allocated
to study the next most promising treatment waiting to be tested. Ethical considerations
prescribe that accumulating data be evaluated frequently, not only with regard to internal
comparisons of safety and efficacy, but also in the light of new information from outside the
trial.
One administrative reason for interim monitoring is to ensure that the experiment is be-
ing carried out correctly, that the subjects are from the right population and satisfy eligibility
criteria and the test procedures are as prescribed in the protocol. An early examination of
interim results helps to reveal the presence of problems which can be corrected before too
many resources are used. Another administrative reason is to examine the assumptions
made in designing the trial. For dichotomous outcome, the sample size calculations rely on
the assumed value of the background incidence rate; for quantitative outcome, the sample
size calculation is often set this variable to be normally distributed with a certain variance.
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For time to event outcome, the accrual period was determined on estimating the subject
accrual rate. An interim analysis result can reveal inappropriate assumptions in time for
adjustments to be made.
There are also economic benefits gained from interim monitoring. For a trial with pos-
itive result, early stopping means that a new product can be put into market earlier. Even
with a negative result, early termination ensures that resources can be allocated to next
most promising treatment waiting to be tested before too many are wasted.
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2.0 INTERIM MONITORING: STOPPING FOR BENEFICIAL
These reasons call for the performance of interim monitoring. However, this involves per-
forming multiple significance tests at different stages during the accumulation of data. As we
know, if we test 20 hypotheses separately at an alpha level of 0.05, the probability that we ob-
serve at least one significant result just due to chance will be inflated to 1-(1−0.05)20 = 0.64.
That is significantly higher than the nominal level of 0.05. That means even if all the tests
are actually non-significant, there is 64% chance of observing at least one significant result.
Similarly, if we compute the test statistic at each interim look in a clinical trial and
declare statistical significance if it ever exceeds some nominal alpha level, say, 1.96, the
probability of eventually reaching a significant result will be inflated.
Methods such as Bonferroni corrections, the false discovery rate and the positive false
discovery rate were proposed in the genomics field to control the type I error by adjusting
alpha level. However, the multiple testing problem in sequential methods is different in na-
ture that the data is accumulating and if at some stage, the null hypothesis is rejected, the
experiment will be terminated.
Armitage et al. [1969] proposed a numerical integration approach to calculate the prob-
ability of exceeding the critical values in repeated significance tests on accumulating data.
The sitting Armitage proposed is to conduct a trial consisting of a series of experiments
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X1,X2,...Xn whose response variable is normally distributed with zero mean and unit vari-
ance. After each experiment is conducted, the cumulative sum Sn =
∑n
i=1Xi is used to test
the null hypothesis. The trial stops when, for the first time, the cumulative sum exceeds a
predetermined boundary yn,
Denote fn the probability density function of Sn in the sequential procedure. It is given
by
fn(Sn) =
∫ yn−1
−yn−1
fn−1(u)
1√
(2pi)
exp {−1
2
(Sn − u)2} du. (2.1)
By recursively using the formula, the density function fn can be defined, with f1 being
the standardized normal density function.
The probability of stopping the trial for superiority before or at the n experiments is
Pn = 1−
∫ yn
−yn
fn(u) du.
Pn − Pn−1 = 1−
∫ yn
−yn
fn(v) dv.− 1 +
∫ yn−1
−yn−1
fn−1(u) du
=
∫ yn
−yn
∫ yn−1
−yn−1
fn−1(v)
1√
(2pi)
exp{−1
2
(u− v)2} dvdu+
∫ yn−1
−yn−1
fn−1(u) du
=
∫ yn−1
−yn−1
fn−1(u)
∫ yn
−yn
1√
(2pi)
exp{−1
2
(u− v)2} dudv +
∫ yn−1
−yn−1
fn−1(u) du
=
∫ yn−1
−yn−1
fn−1(u){1 +
∫ yn
−yn
1√
(2pi)
exp{−1
2
(u− v)2} dv} du
=
∫ yn−1
−yn−1
fn−1(u){1 + 1− 2Φ(yn − u)} du
= 2
∫ yn−1
−yn−1
fn−1(u){1− Φ(yn − u)} du
An alternative form would be:
Pn − Pn−1 = 2
∫ ∞
yn
∫ yn−1
−yn−1
fn−1(u)
1√
(2pi)
exp {−1
2
(u− v)2} dvdu.
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Armitage [1975] used Newton-Cotes formula and Simpson’s formula to evaluate the right
hand side of (2.1).
This numerical quadrature method was later used by other statisticians to approximate
the type I error rates and exit probabilities in sequential methods.
To show how bad the naive method could be, we considered performing interim analyses
in three different situations. The probabilities of exceeding critical levels in repeated signif-
icance tests on accumulating data is given by Table 1.
First, we consider performing interim looks frequently at early stage, say the time points
set to be at 1/16, 1/8, 1/4, 1/2 and the end of the trial. 1/2 means the value of the out-
come variable is ascertain on half of the subjects. Then we consider randomly selecting time
points in the trial, except for the definitive analysis at the end of the trial. Last, we consider
situation that the interim analyses are performed at the late stage of the trial, say 1/2, 3/4,
7/8, 15/16 and the end of the trial for a trial with five looks. The results in the table is
integrated using algorithm proposed by Schoenfeld [2001].
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Table 1: Type 1 error rates by the total number and
timing of looks for a two-tailed test at α = 0.05 in three
situations
N early monitoring random monitoring late monitoring
2 0.0831 0.0816 0.0831
3 0.1135 0.1039 0.0973
4 0.1424 0.1222 0.1039
5 0.1702 0.1369 0.1073
6 0.1971 0.1490 0.1090
7 0.2232 0.1600 0.1100
8 0.2483 0.1704 0.1105
9 0.2727 0.1783 0.1108
10 0.2963 0.1869 0.1110
11 0.3191 0.1932 0.1110
12 0.3412 0.1999 0.1111
13 0.3625 0.2080 0.1111
14 0.3832 0.2120 0.1111
15 0.4032 0.2176 0.1112
16 0.4225 0.2225 0.1112
17 0.4413 0.2263 0.1112
18 0.4594 0.2329 0.1112
19 0.4769 0.2359 0.1112
20 0.4939 0.2397 0.1112
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From table 1, we can see that repeated significance tests without adjusting alpha level
lead to the inflated type I error rate. The probabilities of exceeding critical levels are sig-
nificantly higher if the tests are taken frequently at the early stage. For a trial with ten
looks, the cumulative type I error can be inflated to 0.2963. That is nearly six times of the
predetermined nominal alpha level.
Armitage [1975] later proposed a useful sequential method by adjusting alpha level for
each test. The idea is that after every observation, a significance test is carried out and if a
nominal significance level α∗ is achieved, the trial is terminated. Here α∗ and the maximum
number of observations N are chosen so that the overall significance level α is set to the
required level, say, 0.05.
2.1 THE POCOCK BOUNDARY
However, the method was applied to only a small fraction of clinical trials because the need
for continuous surveillance of every observation can be very difficult and extremely inef-
ficient. Proschan et al. [2006] adapted the method into a group sequential design, which
divides patient entry into a number of equal-sized groups so that the decision to stop the
trial or continue is based on repeated significance tests of the accumulated data after each
group is evaluated.
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For a clinical trial with two treatments, A and B, a homogeneous sample of patients was
randomized into two treatments, so each consecutive group has n patients. The maximum
number of interim looks is denoted as N. Let the response of the treatments is a normal
random variable with unknown mean µA and µB and known variance σ
2. Denote x¯Aj and
x¯Bj the sample means of treatment response for the jth interim analysis.
d¯i =
i∑
j=1
(x¯Aj − x¯Bj)/i
is N(µA−µB, 2σ2/in) After ith interim analysis, the p value for a two-sided significance test
of the null hypothesis of µA = µB is
Pi = 2[1− Φ{
√
(in)d¯i/
√
2σ}]
Pocock set the nominal significance level α∗ for each test. If Pi < α∗, one stops the trial,
claiming treatment difference exists. If Pi > α
∗, for all i=1,2, ..., N, The trial ends, declaring
that there is no treatment difference. Here α∗ and N is chosen, so the overall significance
level of α is controlled. Since (x¯Aj − x¯Bj) for j=1,2, ..., N is normally distributed with mean
µA−µB and variance 2σ2/n, given α and N, the nominal α∗ does not depend on n. Compared
to the standard sequential method proposed by Armitage, Pocock was actually interested in
small value of N.
Table 2 gives the Pocock boundaries at alpha level of 0.05 and 0.01. For example, a
ten-look trial with overall alpha level 0.05, the nominal alpha is set to be 0.0106 for each
significance test.
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Table 2: the nominal significance level α∗ and corre-
sponding z-score for normal group sequential testing,
with known variance, by the number of group N and
overall significance level α
α = 0.05 α = 0.01
looks α∗ z α∗ z
2 0.0293 2.179 0.0056 2.772
3 0.0220 2.290 0.0041 2.873
4 0.0182 2.362 0.0033 2.939
5 0.0158 2.414 0.0028 2.987
6 0.0141 2.454 0.0025 3.024
7 0.0129 2.486 0.0023 3.053
8 0.0120 2.513 0.0021 3.078
9 0.0112 2.536 0.0019 3.099
10 0.0106 2.556 0.0018 3.117
11 0.0101 2.573 0.0017 3.133
12 0.0097 2.588 0.0016 3.148
13 0.093 2.602 0.0016 3.161
14 0.0089 2.615 0.0015 3.172
15 0.0086 2.627 0.0015 3.183
16 0.0084 2.637 0.0014 3.193
17 0.0081 2.647 0.0014 3.202
18 0.0079 2.656 0.0013 3.210
19 0.0077 2.665 0.0013 3.218
20 0.0075 2.672 0.0013 3.225
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2.2 THE O’BRIEN-FLEMING BOUNDARY
The Pococks procedure requires the same level of evidence for early and late looks in a trial.
However, people prefer to require a greater level of evidence to stop the trial in early stage
when there is large variability. Also, most of the probabilities are dedicated to early looks
in Pocock’s procedure while we do not want to pay such a high price at the end of the trial.
To solve these problems, O’Brien and Fleming [1979] proposed an alternative method to
periodically review the results accumulating from the study, allowing for the early termina-
tion of the trial.
The proposed boundaries allow the exit probabilities increase as the information avail-
able increases. Returning to Pocock’s example, a trial with n looks, for the ith look, O’Brien
and Fleming O’Brien and Fleming [1979] proposed to reject the null hypothesis and stop
the trial if the Z-score exceeds P (n, α)/(i/n)1/2, where P (n, α) is pre-determined so that the
total type I error rate is controlled at α. If the null is not rejected at any of the interim
analyses and the test statistic at the definitive analysis does not exceed P (n, α), the study
is concluded with the result that the null hypothesis cannot be rejected at the α significance
level. The calculation of the O’Brien-Fleming boundaries can be done by gradually adjusting
and choosing the value of p(n, α) so that the total type I error rate is α.
Table 3 Gives the O’Brien-Fleming boundary P (n, α) for a two-tailed test at α = 0.05 and
0.01 and different number of looks. For example, the tabled value for ten looks and α = 0.05
is P (10, 0.05) = 2.087. The boundaries for Z(1/10), ..., Z(10/10) would be 2.087/(1/10)1/2 =
6.600, 2.087/(2/10)1/2 = 4.667, 2.087/(3/10)1/2 = 3.810, ..., 2.087/(10/10)1/2 = 2.087.
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Table 3: Approximate Values of the OBrien-Fleming
boundary P(n,α) by the number of looks and overall sig-
nificance level α
looks α = 0.05 α = 0.01
2 1.978 2.580
3 2.005 2.595
4 2.025 2.610
5 2.041 2.622
6 2.053 2.632
7 2.064 2.641
8 2.073 2.648
9 2.080 2.655
10 2.087 2.660
11 2.093 2.666
12 2.098 2.670
13 2.103 2.674
14 2.107 2.678
15 2.111 2.682
16 2.114 2.685
17 2.118 2.688
18 2.121 2.691
19 2.124 2.693
20 2.126 2.696
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Table 4 and table 5 give the cumulative type I error rates and exit probabilities given by
O’Brien-Fleming boundaries, respectively.
Table 4: Cumulative type I error rates of the OBrien-
Fleming boundaries by number of looks
looks
2 0.0026 0.025
3 0.0003 0.0071 0.0249
4 < 0.0001 0.0021 0.0104 0.025
5 < 0.0001 0.0006 0.0044 0.0128 0.0249
6 < 0.0001 0.0002 0.0019 0.0066 0.0145 0.025
7 < 0.0001 0.0001 0.0008 0.0035 0.0085 0.0158 0.025
8 < 0.0001 < 0.0001 0.0004 0.0018 0.005 0.01 0.0168 0.0249
9 < 0.0001 < 0.0001 0.0002 0.001 0.003 0.0064 0.0114 0.0176 0.025
10 < 0.0001 < 0.0001 0.0001 0.0005 0.0018 0.0041 0.0077 0.0125 0.0183 0.025
13
Table 5: Exit probabilities of the O’Brien-Fleming
boundaries by number of looks
looks
2 0.0026 0.0224
3 0.0003 0.0069 0.0178
4 < 0.0001 0.0021 0.0083 0.0145
5 < 0.0001 0.0006 0.0038 0.0083 0.0122
6 < 0.0001 0.0002 0.0017 0.0047 0.0079 0.0105
7 < 0.0001 0.0001 0.0008 0.0026 0.005 0.0073 0.0092
8 < 0.0001 < 0.0001 0.0003 0.0015 0.0032 0.005 0.0068 0.0082
9 < 0.0001 < 0.0001 0.0002 0.0008 0.002 0.0035 0.0049 0.0063 0.0074
10 < 0.0001 < 0.0001 0.0001 0.0004 0.0012 0.0024 0.0036 0.0048 0.0058 0.0067
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2.3 COMPARISON OF POCOCK AND O’BRIEN BOUNDARIES
Pocock procedure requires same level of evidence at the early and late looks, making it
easy to stop at the early stage. While O’Biren-Fleming procedure makes it much more dif-
ficult to stop early and it extracts a smaller price at the end compared to Pocock’s procedure.
The Pocock cumulative type I error rate increases dramatically in the early stage but
slowly at the end. In contrast, the O’Biren-Fleming cumulative type I error rate increases
very slowly at the beginning and increases sharply at the end.
2.4 INFORMATION FRACTION AND BROWNIAN MOTION
The Pocock and O’Brien-Fleming boundaries both require a pre-specified number of equally
spaced looks, but people want more flexibility. They may want to monitor the trial more
frequently if the statistic in prior test is near the boundary or they may want to postpone a
meeting if the statistic is far away from the boundary.
To construct boundaries that do not require pre-specified number or the timing of the
looks, the concept of information time has to be briefly introduced here. Details can be
found at [Lan and Zucker, 1993] and [Proschan et al., 2006].
Assume X1, X2, ..., XN , are independently and identically distributed (i.i.d) random
variables with unknown mean θ and known variance σ2. To test the null hypothesis H0 :
θ = 0, We use the z statistic
ZN =
SN√
VN
15
where SN =
∑N
i=1Xi and VN = V ar{SN} = Nvar{Xi} For an interim analysis after nth
observation is evaluated,
ZN =
Sn + SN − Sn√
VN
=
Sn√
VN
+
SN − Sn√
VN
(2.2)
Sn and SN − Sn are independent, so the two components in (2.2) are independent.
t = vn/vN is called information fraction, which measures how far a trial has processed. In
this case, it is the fraction of patients enrolled relative to the planned sample size, n/N. t=0
means the beginning of the trial and t=1 means the end of the trial.
Denote n(t) as the information after results of nth patients available. Define Z(t) =
Zn(t) =
Sn√
vn
, and define
B(t) =
Sn√
VN
=
√
tZ(t) (2.3)
At the end of the trial t = 1 , B(1) = Z(1) = YN√
VN
So (2.2) becomes B(1) = B(t)+B(1−t)
, which implies that the change in B score from now to the end of the trial B(1-t) is inde-
pendent of the current B-score, B(t).
More generally, B(t) has independent increments, meaning that changes in B values over
non-overlapping intervals are independent, which is an advantage of using B score instead
of z score.
From (2.3), Var(B(t)) = t Var{Z(t)} = t,
For ti < tj,
Cov{B(ti), B(tj)} = cov{ Sni√
Vni
,
Snj√
Vnj
} = ti
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So the distribution of B(t) has these properties,
E{B(t)} = 0
V ar{B(t)} = t
Cov{B(ti), B(tj)} = ti, for ti < tj
Which correspond to the properties of Z(t),
E{Z(t)} = 0
V ar{Z(t)} = 1
Cov{Z(ti), Z(tj)} =
√
ti
tj
, for ti < tj
Note that B(t) is defined only at the discrete information times t=0, 1/N, ..., N/N. It
can be extended to the continuous time scale (τ ∈ [0, 1]) by setting B(τ) = 0 for τ < t1 and
B(τ) = B(tn) = B(n/N) for τ in the interval [tn, tn+1].
As N goes infinity, the set of t at which BN(t) is non-differentiable becomes more and
more dense. In the limit, we get standard Brownian motion, which is defined as a stochastic
process {B(τ) : τ ∈ [0, 1]} such that for any τ1 < τ2 < · · · < τp ∈ [0, 1], the random vec-
tor {B(τ1), ..., B(τp)} has a multivariate normal distribution with mean zero and covariance
given by cov(B(τq), B(τr)) = min{τq, τr}. Interim monitoring often uses Brownian motion
approximation because the properties of Brownian motion is well studied.
Next, consider a clinical trial with binary outcomes, say success or failure. Let SA(i)
and SB(i) the indicators for success for the ith pair of subjects randomized into treatments
A and B, respectively. Denote Di as the difference: Di = SA(i) − SB(i). Assuming that
SA(i)s and SB(i)s are i.i.d. and follow a Bernoulli distribution with success probability p,
then Dis are i.i.d variables with mean 0 and variance 2p(1 − p). The test statistic for the
two-group comparison is given by ZN =
∑N
1 Di√
vN
, where vN = var(SN) = 2Np(1 − p). p is
17
usually approximated by the sample proportion in calculations. For unpaired trials, the test
statistic is often calculated as
ZN =
√
N(p¯A − p¯B)√
2pˆ(1− pˆ)
with p¯A and p¯B as the group-wise proportion of successes and pˆ the pooled proportion of suc-
cesses. Brownian motion still provides a good approximation for trials with a binary outcome.
Consider the time-to-event response. Still compare the treatment effect of A and B. For
simplicity, consider the event that can only happen only once for each patient. Here, denote
N as the total number of patients with events at the end of a trial. For the ith event time, let
Oi be the indicator that whether the patient with event is in the treatment group A : Oi = 1
if the ith event occurs in treatment A, otherwise Oi is 0. Let YA and YB be the number of
patients at risk just prior to the ith event. Then the expectation of Oi is Ei = YA/(YA +YB)
under the null hypothesis that there is no difference in the event risk between treatment
groups A and B. Conditioning on the marginal values YA and YB, Oi follows a Bernoulli
distribution with success parameter Ei. Let Di = Oi − Ei. Under the null hypothesis,
Di has mean 0 and variance Vi = Ei(1 − Ei). Unconditionally, the Dis are uncorrelated,
mean-zero random variables with variance Vi under the null hypothesis. Conditioning on N ,
vN = var(SN) =
∑N
i=1 var(Di) = E(
∑
Vi). The log-rank statistic is given by ZN =
∑N
i=1Di√
vN
,
where vN ≈
∑N
i=1 Vi.
The information fraction in survival settings is defined in terms as patients with events
instead of patients enrolled. If we condition on N and n, the covariance structure of Brownian
motion holds. The Brownian motion is again a good approximation to the process B(t). A
practical problem is that at the interim analysis, we would not know or approximate vN .
Under the null hypothesis, E(Vi) = E{Ei(1−Ei)} ≈ (1/2)(1−1/2) = 1/4. Without making
any assumptions about the form of the survival curve, this simple argument shows that the
variance of Di is approximately 1/4. It follows that vN ≈ N/4. This leads to that the
information fraction by the nth event is t = n/N .
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2.5 SPENDING FUNCTIONS
Spending functions were discussed by Proschan et al. [2006] to construct boundaries that do
not need pre-determined number or timing of looks, giving more flexibility to monitoring.
The key to making boundaries more flexible is to consider the cumulative type I error
rate used by different information time. We used a trial with five and ten interim looks as
an example. The type I error rates at different information time were given in Table 6.
Table 6: Cumulative type 1 error rates used by the
O’Brien-Fleming procedure with five and ten looks and
one-tailed α = 0.025
number of looks 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
5 NA 0.0000 NA 0.0006 NA 0.0045 NA 0.013 NA 0.025
10 0.0000 0.0000 0.0000 0.0005 0.0018 0.0041 0.0077 0.012 0.018 0.025
Table 6 shows that type I error rates used by the information fractions common to
five and ten looks, namely t=0.2, 0.4, 0.6, 0.8, 1 are almost the same for 5 and 10 looks.
Therefore, doubling the number of looks does not considerably change its value at previously
existing support points. Imagine doubling the number of looks to infinity. The O’Brien-
Fleming boundary ak approaches α as k →∞ , where α is such that Pr(B(s) > α for some
s ≤ 1) = α. The probability of crossing the boundary by time t is
α1(t) = Pr(B(s) > α for some s ≤ 1) = α
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α1(t) is an increasing function defined on all of [0,1] with α1(0) = 1 and α1(1) = α.
Instead of specifying the number and timing of looks, we can specify a spending function
telling how much alpha to use by information time t.
2.5.1 Linear spending function
To illustrate how the spending function works, we use a linear spending function as an ex-
ample.
let
α2(t) = αt, 0 ≤ t ≤ 1
with α = 0.025 and one-tailed testing. Suppose the first look occurs at information fraction
t = 0.2. We spend α2(0.2) = 0.025(0.2) = 0.005 at the first interim analysis and there-
fore determine a critical value c1 such that Pr{Z(t1) > c1} = 0.005. The corresponding
boundary is c1 = Φ
−1(0.995) = 2.576. We reject the null hypothesis at the first analysis if
Z(0.20) > 2.576. Suppose this does not happen, the next interim analysis occurs at informa-
tion time t=0.4. The cumulative type I error rate by t=0.4 is α2(0.4) = 0.025(0.4) = 0.01.
We determine the boundary c2 such that Pr[{Z(0.2) > 2.576} ∪ {Z(0.4) > c2}] = 0.01.
We use numeric integration to get the value of c2. Thus, we reject the null hypothesis at
the second analysis if Z(0.4) > 2.492. Suppose this does not happen and the next analysis
occurs at t=0.6. The cumulative type I error at t=0.6 is 0.025(0.6)=0.015. We determine
the value c3 such that Pr[{Z(t1) > c1} ∪ {Z(0.4) > 2.492} ∪ {Z(0.6) > c3}] = 0.015, which
yields c3 = 2.411. We reject the null hypothesis at the third analysis if Z(0.6) > 2.411.
Suppose that does not happen either and the final analysis occurs at the end of the trial.
The cumulative type 1 error rate by t=1 is α2(1) = 0.025(1) = 0.025 ,which yields c4=2.186.
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In this example we found ci iteratively such that
Pr[∪ji=1{Z(ti) > ci}] = α(tj), j = 1, ..., k
Pr[∩ji=1{Z(ti) ≤ ci} ∪ {Z(tj) > cj} = α(tj)− α(tj−1), j = 1, ..., k
Here, we used linear function as an example, but we could have used other spending functions.
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3.0 STATISTICAL POWER
Statistical power is the probability of rejecting the null hypothesis when the alternative
hypothesis is true. It is the likelihood of distinguishing an effect of certain size from pure
chance. A study might easily detect large treatment difference, but less likely to detect a
subtle treatment difference. In clinical trials, we might miss a valuable therapy because of
lacking statistical power to detect the treatment effect. In fact, in a sample of randomized
clinical trials published between 1975 and 1990 with negative results, Moher et al. [1994]
found that 64% of the studies can not detect a 50% relative difference. Even a treatment
can reduce the symptoms by 50% compared to other treatment, there is no sufficient data
to conclude that is efficient.
3.1 UNCONDITIONAL POWER
Therefore, adequate sample size and power are essential for a well-designed clinical trial. For
asymptotically normal statistics with mean θ and unit variance, we equate θ, the expected
z-score, to zα/2 + zβ and solve for either the sample size or power.
For power calculation:
θ = zα/2 + zβ
Power = 1− β = Φ(θ − zα/2)
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Consider a trial with dichotomous outcome using a test of proportions. The expected
death in the control arm is 0.6. And we want to have 80 percent power to detect a 20 percent
reduction in the treatment arm.
The expected z-statistic is θ =
√
N(pA−pB)√
2pˆ(1−pˆ) , where pA = 0.6 and pB = 0.4, pˆ = (0.6 +
0.4)/2 = 0.5. To achieve 80 percent power, we set θ = 1.96 + 0.85 = 2.81 and solve for N,
which yields N=2(0.5)(1−0.5)(1.96+0.85)
2
(0.6−0.4)2 ≈ 99 patients per arm.
3.2 CONDITIONAL POWER
As we mentioned, power is the probability to detect the treatment difference when it exists.
So if the power is low, it is unlikely to find statistically significant results. Experiments with
low power should not proceed. However, it becomes more clear as the experiment proceeds.
Conditional power is the probability of correctly rejecting the null hypothesis at the end
of the trial, given accumulating data. If we approximate conditional power using Brownian
motion, that is at time t = 1, B(1) > zα/2 given B(t)=b.
B(1) = B(1)−B(t) +B(t)
As previously mentioned, B(1)-B(t) is independent of B(t) and have mean and variance
E{B(1)−B(t)} = θ(1)− θ(t) = θ(1− t)
Cov{B(1), B(t)} = cov{B(t) +B(1)−B(t), B(t)} = var{B(t)}
V ar{B(1)−B(t)} = var{B(1)}+ var{B(t)} − 2cov{B(1), B(t)} = 1 + t− 2t = 1− t
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given B(t)=b,B(1)=b+B(1)-B(t) is normally distributed with variance 1-t and mean
E{B(1)|B(t) = b} = b+ E[B(1)−B(t)] = b+ θ(1− t)
Conditional power is
CPower = Pr[|B(1)| ≥ Z1−α/2|B(t) = b]
CPower = 1− Φ(zα/2 − E{B(1)|B(t) = b}√
1− t )
Conditional power increases as θ increases.
Under the null hypothesis θ = 0,
E0{B(1)|B(t) = b} = b
The empirical estimate for θ is θˆ = B(t)/t = b/t. Under this current trend hypothesis,
Eθ{B(1)|B(t) = b} = b/t = θˆ
We will use an example with dichotomous outcome to illustrate the application of con-
ditional power.
Suppose that at one interim analysis, 36 of 59 patients in the control arm developed
events and 28 of 61 patients in the treatment arm have events. The data is summarized in
table 7.
Table 7: Interim data for dichotomous response example
Event
Yes No
Control 36 23 59
Treatment 28 33 61
64 56 120
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The information fraction τ = (1/59 + 1/61)−1/(2/99)−1 = 0.61/ pˆtreatment = 28/61 =
0.46,pˆcontrol = 28/61 = 0.61, so pˆ = (0.46+0.61)/2 = 0.535 selected patient has success. The
z-statistic is given by ZN =
∑N
1 Di√
vN
, where vN = var(SN) = 2Np(1 − p). p is approximated
by the sample proportion.
Z(0.61) =
√
N(p¯A − p¯B)√
2pˆ(1− pˆ) =
√
99(0.61− 0.46)√
2(0.535)(1− 0.535) = 2.12
B(0.61) =
√
(0.61)Z(0.61) = 1.66
Under the original event probaility assumptions in the two arms, the drift parameter is
θ = 1.96 + 0.85 = 2.81 so the condition mean of B(1) given B(0.61)=1.66 is 1.66+2.81(1-
0.61)=2.76. Conditional power under the original assumptions is
CPower(0.61) = 1− Φ(1.96− 2.76√
1− 0.61 ) = 1− Φ(−1.28) = 0.90
Using the empirical estimates of event probabilities in the two arms corresponds to using
the empirical drift parameter estimate B(t)/t=1.66/0.61=2.72.the condition mean of B(1)
given B(0.61)=1.66 is 1.66+2.72(1-0.61)=2.72.
CPower(0.61) = 1− Φ(1.96− 2.72√
1− 0.61 ) = 1− Φ(−1.21) = 0.89
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4.0 APPLICATIONS
Here, we use two phase III clinical trials to demonstrate how decisions can be made upon
results of interim monitoring and conditional power.
4.1 APPLICATION IN THE NASBP B-38 TRIAL
A phase III adjuvant therapy trial was conducted to compare the two regimens of chemother-
apy: Docetaxel/Doxorubicin/Cyclophosphamide (TAC) and DD AC Followed by DD Pacli-
taxel Plus Gemcitabine (DD AC→ PG) for women with node-positive breast cancer.
The aim of the study is to determine whether the DD AC→ PG regimen is superior to
the TAC regimen in terms of Disease Free Survival (DFS) and Survival (S).
The study was conducted in women with operable, invisible carcinoma of the breast with
histologically positive axillary nodes. Patients were stratified by number of positive nodes,
hormone receptor status, and type of surgery and planned radiotherapy and then randomized
to one of the three chemotherapy regimens. Women with ER-positive and /or PgR-positive
tumors received hormonal therapy following completion of chemotherapy. Accrual of 4800
patients were completed in four years.
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Five interim analyses were planned when the minimum number of events in both pairs
of groups reaches 204, 286, 368, 450 and 532, respectively. A final analysis was planned
when the minimum number of events in both pairs reaches 613. At each interim analyses,
the hypotheses was tested: whether DD AC→ PG is superior to AC.
Three different alpha spending functions were used to determine the upper boundaries.
For the Pocock-like boundaries, the alpha spending function is α∗(t) = αln{1 + (e − 1)t}.
For linear function, the alpha spending function is α∗(t) = αt. For O’Brien-Fleming-like
function is α∗(t) = 2{1− Φ(zα/2/
√
t)}. Details can be found in [Proschan et al., 2006].
The overall alpha level was controlled to be 0.025. Exceeding upper boundaries will lead
to the conclusion that DD AC→ PG is more beneficial than TAC and the trial will be ter-
minated for efficiency. The cumulative type I error rates and boundaries are given in Table
8 and Table 9, respectively.
Table 8: One-sided cumulative type I error rates given by
different alpha spending functions and information frac-
tion for NASBP B-38 trial
t1 t2 t3 t4 t5 t6
information fraction 0.333 0.467 0.600 0.734 0.868 1.000
Pocock-like 0.011 0.015 0.018 0.020 0.023 0.025
linear-like 0.008 0.012 0.015 0.018 0.022 0.025
O’Brien-Fleming-like <0.001 0.002 0.006 0.011 0.018 0.025
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Table 9: Boundaries given by different alpha spending
functions and information fraction for NASBP B-38 trial
t1 t2 t3 t4 t5 t6
information fraction 0.333 0.467 0.600 0.734 0.868 1
Pocock-like 2.280 2.443 2.450 2.445 2.437 2.431
linear-like 2.395 2.489 2.451 2.404 2.359 2.317
O’Brien-Fleming-like 3.398 2.890 2.579 2.368 2.215 2.100
If we want to have a fair chance to stop the trial, we would consider using the linear
alpha spending function. If we want to resist stopping too early then we would consider using
O’Brien-Fleming alpha spending function. As we can see in the table, the exit probabilities
in the early stage is really small.
By September 30, 2011, there were 207 deaths in DD AC → PG treatment group and
181 deaths in TAC treatment group. The information is summarized in Table 10.
Table 10: Interim data for NASBP B-38 trial
Stratum Treatment Total Failed Censored Percent Censored
1 DD AC → PG 1630 207 1423 87.3
2 TAC 1630 181 1449 88.9
Total 3260 388 2872 88.1
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We expected 613 deaths by the end of the study. The current information fraction is
t = 388/613 = 0.633. The log hazard ratio estimate and log-rank statistic are ln(0.889) =
−0.118 and Z(0.633) = 1.902. The B-value is B(0.633) = √0.633(1.902) = 1.511.
The empirical estimate of the drift parameter is B(0.633)/0.633 = 2.389. The expected value
of B(1) given B(0.633) = 1.511 is 1.511 + 2.389(1− 0.633) = 2.389, so conditional power is
CPower(0.633) = 1− Φ(1.96− 2.389√
1− 0.633 ) = 1− Φ(−0.71) = 0.76
Under the originally assumed log hazard ratio, the drift parameter is θ =
√
(N/4)δ =√
613/4ln(1/0.75) = 3.561, and the expected B-value at the end of the trial is 1.511 +
3.561(1− 0.633) = 2.818. Conditional power is
CPower(0.633) = 1− Φ(1.96− 3.561√
1− 0.633 ) = 1− Φ(−2.643) = 0.99
The conditional power under both assumptions are relatively high, indicating that there
is high chance of getting a significant result at the end of the trial.
4.2 APPLICATION IN THE NASBP B-40 TRIAL
A randomized phase III trial of neoadjuvant therapy was conducted to determine whether
the addition of bevacizumab to docetaxel-based regimens followed by AC will increase the
pathologic complete response (pCR) rates in patients with palpable and operable HER2-
negative breast cancer.
Three statistical analyses were planned for the outcome of pCR in breast. Two interim
analyses were planned when the available pathologic response status reaches 400 and 800.
The trial would be considered to assign bevacizumab to all subsequently enrolled patients
if it has enough evidence that docetaxel based regimen with becacizumab is superior than
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without becacizumab. As in the NASBP B-38 study, three alpha spending functions are used
to determine the boundaries and the final significance level is adjusted to be 0.05. Exceeding
the boundaries will lead to the conclusion that with bevacizumab is more beneficial. Bound-
aries and corresponding type I error rates are given in Table 11 and Table 12, respectively.
Table 11: Two-sided cumulative type I error rates given
by different alpha spending functions and information
fraction for NASBP B-40 trial
t1 t2 t3
infromation fraction 0.333 0.667 1.000
Pocock-like 0.023 0.038 0.050
linear-like 0.017 0.033 0.050
O’Brien-Fleming-like 0.002 0.022 0.051
Table 12: Bundaries given by different alpha spending
functions and information fraction for NASBP-40
t1 t2 t3
infromation fraction 0.333 0.667 1.000
Pocock-like 2.002 2.001 1.975
linear-like 2.128 2.001 1.880
O’Brien-Fleming-like 2.841 2.026 1.728
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The sample size for the trial is 1200 patients (600 per arm). By February 23, 2010, pCR
status was available from 806 patients with 401 assigned to the arms with Bevacizumab.
Table 9 gives the proportion of patients with events in both arms. The proportions of pCR
were 30.4%(123/405) and 34.7%(139/401) for the two groups, respectively.
Table 13: Interim data for NASBP B-40 trial
pCR
Yes No
Bevacizumab 139 278 401
non-Bevacizumab 123 266 405
262 544 806
The information fraction t = (1/401 + 1/405)−1/(2/600)−1 = 0.672.
For the Bevacizumab group, the estimated pCR at that time is pˆBev = 139/401 = 0.347,
For the non-Bevacizumab group, the estimated pCR at that time is pˆnon = 123/405 = 0.304,
so pˆ = (0.304 + 0.347)/2 = 0.326 selected patient has success. The z-statistic is given
by ZN =
∑N
1 Di√
vN
, where vN = var(SN) = 2Np(1 − p). p is approximated by the sample
proportion.
Z(0.672) =
√
N(p¯A − p¯B)√
2pˆ(1− pˆ) =
√
600(0.347− 0.304)√
2(0.326)(1− 0.326) = 1.123
B(0.672) =
√
(0.672)Z(0.672) = 0.921
Under the original event probaility assumptions in the two arms, the drift parameter is
θ = 1.96+0.85 = 2.81, so the condition mean of B(1) given B(0.672)=0.921 is 0.921+2.81(1-
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0.672)=1.843. Conditional power under the original assumptions is
CPower(0.672) = 1− Φ(1.96− 1.843√
1− 0.672 ) = 1− Φ(0.21) = 0.417
The conditional power under the original assumption is relatively low. There is fairly
high probability of failing to reach a statistically significant result at the end of the trial.
Using the empirical estimates of event probabilities in the two arms corresponds to using
the empirical drift parameter estimate B(t)/t=0.921/0.672=1.37.the condition mean of B(1)
given B(0.671)=0.921 is 0.921+1.37(1-0.672)=1.37.
CPower(0.672) = 1− Φ(1.96− 1.37√
1− 0.672) = 1− Φ(1.03) = 0.152
Thus, if the empirical trend is true, then we have 15.2 percent chance of a statistically
significant benefit at the end of the trial.
When the test statistics exceed the upper boundaries in interim looks, we would consider
terminating the trial for superiority. In this case, the new treatment under investigation
can be put into market as soon as possible. However, if a test statistic is far away from the
boundaries in the interim looks, we will be concerned whether we could obtain a significant
result at the end of the trial. In this situation, we would calculate the conditional power.
And based on the conditional power, decisions might be made to stop the trial if it is unlikely
to claim the superiority of the new treatment in the end so that further resources would not
be wasted. However, this kind of decision is difficult when so many efforts have been put
into the trial. Therefore, investigators usually also consider other aspects of the trial such
as economics, toxicity of the drugs while making a decision on the trial.
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